MOSAIC: A cohort study of human mpox virus disease
Authors:
- Elise PesonelEPElise Pesonel
- Isabelle HoffmannIHIsabelle Hoffmann
- Laetitia GuiraudLGLaetitia Guiraud
- Josephine BournerJBJosephine Bourner
- Alpha DialloADAlpha Diallo
- Jake DunningJDJake Dunning
- Peter HorbyPHPeter Horby
- Sabrina KaliSKSabrina Kali
- Cédric LaouénanCLCédric Laouénan
- France MentréFMFrance Mentré
- Laura MersonLMLaura Merson
- Diana MolinoDMDiana Molino
Open Access
- 12 December 2023
- journal article
- research article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 8, 415
Abstract
Background Human mpox is a viral disease caused by an Orthopoxvirus, human mpox virus (hMPXV), typically causing fever and a rash. Mpox has historically been endemic to parts of Central and West Africa, with small numbers of imported cases reported elsewhere, but starting May 2022 an unprecedented global outbreak caused by clade IIb hMPXV was reported outside traditionally endemic countries. This prompted the initiation of MOSAIC, a cohort study implemented in Europe and Asia that aims to describe clinical and virologic outcomes of PCR-confirmed hMPXV disease, including those who receive antiviral therapy. The focus of this article, however, is on describing the study protocol itself with implementation process and operational challenges. Methods MOSAIC recruits participants of any age with laboratory-confirmed mpox disease who provide informed consent. Participants enrol in the cohort for a total of six months. Blood, lesion and throat samples are collected at several timepoints from the day of diagnosis or the first day of treatment (Day 1) until Day 28 for PCR detection of hMPXV. Clinical data are collected by clinicians and participants (via a self-completion questionnaire) for six months to characterize the signs and symptoms associated with the illness, as well as short- and more long-term outcomes. Discussion The design and prompt implementation of clinical research response is key in addressing emerging outbreaks. MOSAIC began enrolment within two months of the start of the international mpox epidemic. Enrolment has been stopped and the last follow-up visits are expected in January 2024. ICTRP registration EU CT number: 2022-501132-42-00 (22/06/2022)Keywords
Funding Information
- Wellcome (215091)
- Bill & Melinda Gates Foundation (OPP1209135)
- MPX-Response (101115188)
This publication has 12 references indexed in Scilit:
- Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022Emerging Infectious Diseases, 2023
- Experiences and challenges with the new European Clinical Trials RegulationResearch Square, 2023
- Tecovirimat for Monkeypox in Central African Republic under Expanded AccessNew England Journal of Medicine, 2022
- MonkeypoxNew England Journal of Medicine, 2022
- Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022New England Journal of Medicine, 2022
- Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virusPLOS Biology, 2022
- Monkeypox: how will we know if the treatments work?The Lancet Infectious Diseases, 2022
- The changing epidemiology of human monkeypox—A potential threat? A systematic reviewPLOS Neglected Tropical Diseases, 2022
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Poxvirus DNA ReplicationCold Spring Harbor Perspectives in Biology, 2013